Tonix Pharmaceuticals Holding Corp (TNXP)
Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)
Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)
📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak financial signals • Minimal market impact expected **Sentiment:** Neutral (50%) **Content type:** Financial